Oxaliplatin Sandoz

Oxaliplatin, the active ingredient in Oxaliplatin Sandoz, is a platinum‑based chemotherapy presented as a solution for intravenous use. It treats colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH USA supplies Oxaliplatin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oxaliplatin Sandoz is a platinum‑based chemotherapeutic agent used in the treatment of cancers that involve the gastrointestinal tract.

- Colorectal cancer: improves survival when combined with fluoropyrimidine chemotherapy. - Gastric cancer: used as part of combination regimens for advanced disease. - Pancreatic cancer: contributes to tumor response in selected combination protocols. - Esophageal cancer: employed in multi‑drug regimens for locally advanced cases. - Small‑cell lung cancer: occasionally incorporated into experimental combination therapies. - Peritoneal carcinomatosis: used in intraperitoneal chemotherapy approaches.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during treatment.

Common Side Effects: - Nausea and vomiting: frequently reported during infusion. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: may be mild to moderate in severity. - Fatigue: generalised tiredness experienced by many patients. - Thrombocytopenia: reduced platelet count observed in blood tests. - Elevated liver enzymes: mild transaminase increases.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including anaphylaxis. - Acute neurotoxicity: sudden onset of muscle cramps or spasms. - Persistent peripheral neuropathy: long‑lasting sensory deficits. - Bone marrow suppression: leading to neutropenia or anaemia. - Renal impairment: decreased kidney function in susceptible individuals. - Cardiac arrhythmias: irregular heart rhythms observed in rare cases.

When using Oxaliplatin Sandoz, clinicians should consider several safety measures to minimise risks.

- Renal function: assess baseline creatinine and monitor regularly. - Neuropathy risk: evaluate pre‑existing peripheral neuropathy before each cycle. - Hematologic monitoring: perform complete blood counts prior to infusion. - Hepatic function: check liver enzymes and bilirubin levels. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks. - Storage: Store below 25°C: keep in the original container, protect from light and moisture.

Oxaliplatin can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use with high‑dose cisplatin or aminoglycosides may worsen kidney injury. - Anticoagulants: increased bleeding risk when combined with warfarin or direct oral anticoagulants. - High‑dose vitamin C: may reduce platinum‑DNA binding efficacy.

Moderate Interactions (Monitor Closely): - Fluoropyrimidines (5‑FU, capecitabine): enhanced neurotoxicity when given together. - Antiemetics (serotonin antagonists): may require dose adjustment for optimal control. - CYP3A4 inhibitors: potential alteration of drug clearance, requiring monitoring.